The U.S. Patent and Trademark Office (USPTO) has issued a new patent granting IP rights for the novel composition of matter and methods of use on the psilocybin-based molecules series…
Read More
Enveric Biosciences (NASDAQ: ENVB) announced that the United States Patent and Trademark Office issued U.S. Patent No. 11,752,130, titled “Carboxylated Psilocybin Derivatives and Methods of Using,” pertaining to the Company’s…
Read More
Claims to novel composition of matter and pharmaceutical drug formulations encompass EVM301 Series of drug candidates, targeting various difficult-to-treat mental health disorders by promoting neuroplasticity without inducing hallucinations CAMBRIDGE, Mass.…
Read More
Poster details advances in screening for non-hallucinogenic, neuroplastogen drug candidates for the treatment of mental health disorders CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology…
Read More
Enveric utilizing AI-backed 3D modeling to identify potential non-hallucinogenic, neuroplastic tryptamine derivative NCEs for its EVM301 Series CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology…
Read More
New patent provides additional composition of matter and methods of use claims for Enveric's tryptamine-derived prodrugs including EB-373, a new chemical entity psilocin prodrug CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ:…
Read More
EB-373, a proprietary psilocin prodrug, is on track to start its first-in-human clinical trial in the fourth quarter of 2023 CAMBRIDGE, Mass. - Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or…
Read More
First-in-human clinical trial investigating Enveric's lead product candidate, EB-373 targeting anxiety disorder expected to initiate in the fourth quarter of 2023 CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or…
Read More
Research details the bioproduction of novel indolethylamine-type drug candidates with potential use in psychiatric medicine CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated…
Read More
